Spyre Therapeutics SYRE 深 滬
等待開盤 09-25 09:30:00 美东时间
87.09
-1.080
-1.22%
華盛通- 最 高87.46
- 今 開87.46
- 成交量 171.32万股
- 最 低 82.93
- 昨 收 88.17
- 總市值 76.79亿
- 52周最高 110.175
- 市盈率 靜 --
- 換手率 1.94%
- 52周最低 15.86
- 委 比 -49.66%
- 總股本 8817.38万
- 歷史最高 318.75
- 量 比 1.02
- 振 幅 5.14%
- 歷史最低 2.66
- 每 手 1
- 風險率 29.43%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多美股大行评级 | 戴尔、Adobe获大行上调目标价；甲骨文绩前目标价遭调低
今日重点评级关注：富国银行：维持Pyxis Oncology"超配"评级，目标价从12美元升至19美元；Oppenheimer：维持Opus Genetics"跑赢大市"评级，目标价从10美元升至20美元
09-10 15:00
美股大行评级 | 多家大行齐上调Robinhood目标价！最高看至150美元；安进股价大跌后评级遭下调
今日重点评级关注：Chardan Capital：维持Hyperion DeFi"买入"评级，目标价从7.3美元升至8.45美元；摩根大通：维持Vera Therapeutics"超配"评级，目标价从76美元升至83美元
09-09 15:36
BTIG Reiterates Buy on Spyre Therapeutics, Maintains $121 Price Target
BTIG analyst Julian Harrison reiterates Spyre Therapeutics (NASDAQ:SYRE) with a Buy and maintains $121 price target.
09-08 23:22
Spyre Announces Potential Best-in-Class SPY003 (anti-IL-23) Part A Induction Results from SKYLINE Trial, Completing Proof-of-Concept for All Three Components of its IBD Combinations
Spyre Therapeutics announced positive 12-week induction data from Part A of the Phase 2 SKYLINE trial for SPY003, a potential best-in-class anti-IL-23 for moderately-to-severely active ulcerative colitis (UC). SPY003 met its primary endpoint with a statistically significant 10.0-point reduction in Robart’s Histopathology Index (RHI) score (p<0.0001) and achieved meaningful clinical remission and endoscopic improvement. The safety profile was cons...
09-08 12:00
Spyre Therapeutics Announces Grants of Inducement Awards
Spyre Therapeutics granted stock options for 2,106 shares and 745 RSUs to a non-executive employee under its 2018 Equity Inducement Plan on September 1, 2026. The stock options have a 10-year term with an exercise price of $88.50, vesting 25% on the first anniversary of the employee's start date and monthly thereafter. The RSUs vest quarterly starting from the first anniversary. The company aims to develop next-generation immunology therapies.
09-04 20:01
美股大行评级 | 潜在涨幅1849.95%！Ascendiant Capital上调IGC Pharma目标价至6美元，维持"买入"评级；迪克体育、财捷遭多家大行下调目标价
今日重点评级关注：Ascendiant Capital：维持IGC Pharma"买入"评级，目标价从5.5美元升至6美元；Ascendiant Capital：维持Quantum Computing"买入"评级，目标价从30美元升至32美元
08-27 08:37
Spyre Therapeutics Stock (SYRE) Tumbles 14% in After-Hours – Here’s What Spooked Investors
Spyre Therapeutics ($SYRE) fell as much as 14% in after‑hours trading on Tuesda...
08-26 06:51
Spyre Therapeutics shares are trading lower after the company announced topline results from the RA sub-study of its Phase 2 SKYWAY basket trial evaluating SPY072 in rheumatic diseases. The results did not meet the company's internal bar to prioritize advancement of SPY072 in RA.
Spyre Therapeutics shares are trading lower after the company announced topline results from the RA sub-study of its Phase 2 SKYWAY basket trial evaluating SPY072 in rheumatic diseases. The results did not meet the company's internal bar to prioritize advancement of SPY072 in RA.
08-26 04:05
